Measures of radiation dose include total air kerma at the interventional reference point, air kerma area product, uoroscopy time, and number of cine images (4). Furthermore, it is recommended that every catheterization laboratory de ne thresholds, with corre- sponding follow-up protocols, for patients who receive a high procedural radiation dose. It is most typical to report total uoroscopy time, but the writing committee recog- nized that this is a limited measure of total radiation exposure and dose. All contemporary interventional x-ray systems report the total air kerma area product (in Gray [Gy]) and air kerma area product (in Gycm2 ). When available, one or both of these measures should be docu- mented in the procedure report in addition to uoroscopy time. At the present time, the writing committee desig- nated this measure for internal quality improvement only to avoid potential unintended consequences, such as op- erators feeling a need to limit additional imaging even when it would be clinically useful (see Appendix C for a summary of the analysis). 5.7. Postprocedural Optimal Medical Therapy Composite Medical therapy, including aspirin, P2Y12 inhibitors, and statins, has been proved to reduce all-cause mortality and cardiovascular morbidity in multiple studies. These medi- cations should be prescribed to all patients who are eligible for them after PCI, except for the rare circumstances in which the life expectancy of the patient is limited or the patient has a known allergy or intolerance. Despite the strong endorsement from the guidelines and their robust evidence base, the use of these medications is less than optimal, particularly for statin therapy. Recently, Borden and colleagues (36) evaluated the use of optimal medical therapy in patients undergoing PCI for stable disease who were enrolled in the National Cardiovascular Data Registry CathPCI Registry. 